Clinical trial
Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of…
NCT00119314 · University of Medicine and Dentistry of New Jersey, Other · Withdrawn
Key facts
| NCT number | NCT00119314 |
|---|---|
| Title | Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin |
| Official title | Carcinoma Unknown Primary: Treatment With Gemcitabine, Docetaxel and Capecitabine (GTX) an Evaluation and Treatment Study of The Cancer Institute of New Jersey Oncology Group |
| Lead sponsor | University of Medicine and Dentistry of New Jersey, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma of Unknown Primary |
| Intervention type | Drug, Procedure |
| Interventions | capecitabine, docetaxel, gemcitabine hydrochloride, positron emission tomography |
| Enrollment | 0 |
| Start date | Jul 1, 2004 |
| Primary completion | Jul 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | Jul 13, 2005 |
| Last update posted | May 27, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: